Condition Directory

Lung Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Lung Cancer. Browse Lung Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 16, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 16, 2026, 4:08 PM EDT

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1147

Shown on this page

Current sort

How Lung Cancer studies are organized in the registry

The registry splits lung cancer records between non-small cell (NSCLC) and small cell (SCLC) disease, and a large share of NSCLC studies are organized around a biomarker rather than the diagnosis alone. If a mutation or marker drives your search, query it directly — it typically appears verbatim in titles. A dedicated non-small cell lung cancer page is also available in this directory.

Terms that often appear in related listings

NSCLC small cell lung cancer EGFR ALK KRAS

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 1105–1116 of 1,147 matching trials for Lung Cancer.

Indexed local directory records.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Stored official records

Open in full search

Conditions: Non Small Cell Lung Cancer, Small Cell Lung Cancer, Soft Tissue Sarcoma, Solid Tumor, Adult
Interventions: AL3818, Nivolumab Injection; Drug
Lead sponsor: Sarcoma Oncology Research Center, LLC; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Cutaneous Melanoma, Endometrial Carcinoma (EC), Non-Small Cell Lung Cancer, Refractory Cancer, Solid Tumor, Adult, Squamous Head and Neck Carcinoma, pMMR/MSS Adenocarcinoma of the Colon or Rectum
Interventions: GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®]; Biological
Lead sponsor: GV20 Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 13
States / cities: Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 9 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Alectinib, Carboplatin, Cisplatin, Datopotamab deruxtecan, Durvalumab, Etoposide, Gefitinib, Necitumumab, Osimertinib, Pemetrexed, Savolitinib, Selpercatinib, Selumetinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 16
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 11 more

Conditions: Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Autologous Dendritic Cell-Adenovirus CCL21 Vaccine, Pembrolizumab; Biological
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Non Small Cell Lung Cancer
Interventions: beta-glucan; Dietary Supplement
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2029
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Advanced Solid Tumor, Colorectal Cancer, Non Small Cell Lung Cancer
Interventions: Atezolizumab, DSP107; Biological
Lead sponsor: Kahr Medical; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 7
States / cities: La Jolla, California • Aurora, Colorado • Lake Mary, Florida + 4 more

Conditions: Colon Cancer, Metastatic Solid Tumor, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
Interventions: 1.0% IP-001 for Injection; Drug
Lead sponsor: Immunophotonics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Coral Gables, Florida • Louisville, Kentucky • Oklahoma City, Oklahoma

Conditions: Advanced Solid Tumor, Cancer, Cutaneous Melanoma, Malignant Neoplasm, Metastatic Cancer, Non-small Cell Lung Cancer, Tumor, Solid
Interventions: Cemiplimab, OR502; Drug
Lead sponsor: OncoResponse, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: Austin, Texas • Irving, Texas • San Antonio, Texas + 1 more

Conditions: Colorectal Cancer, Melanoma, Non-small Cell Lung Cancer, Renal Cell Cancer
Interventions: IBI363; Drug
Lead sponsor: Innovent Biologics (Suzhou) Co. Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 9
States / cities: San Francisco, California • Ocala, Florida • Plantation, Florida + 5 more

Conditions: Breast Cancer, Endometrial Cancer, Gastric Cancer, Geriatric Oncology, Head and Neck Cancers, Lung Cancer, Metastatic Breast Cancer, Metastatic Cancer, Ovarian Cancer, Prostate Cancers, Survivorship
Interventions: Digital Health Coaching Program, Fitbit; Behavioral · Device
Lead sponsor: Pack Health; Industry
Eligibility: 18 Years and older
Enrollment: 625 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 7
States / cities: Gainesville, Florida • Boston, Massachusetts • Omaha, Nebraska + 3 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Not listed
Lead sponsor: Scientific Institute San Raffaele; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Miami, Florida • New York, New York • Morgantown, West Virginia

Conditions: Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma (Kidney Cancer), Solid Tumor
Interventions: NDI-101150, Pembrolizumab; Drug
Lead sponsor: Nimbus Saturn, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 19
States / cities: Scottsdale, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 15 more

About this Lung Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Lung Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Lung Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Lung Cancer clinical trials

How Lung Cancer studies are organized in the registry

Filter and sort this condition

Stored official records

Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer

The Effect of Beta-glucan in Non-Small Cell Lung Cancer

A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors

Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

A Study of IBI363 in Subjects with Advanced Solid Malignancies

Comprehensive Outcomes for After Cancer Health

Analysis of RATS, VATS and Open Lung Resections After Neoadjuvant Chemo-immunotherapy in Patients Performed in Five Referred Centers

A Study of NDI 1150-101 in Patients With Solid Tumors

About this Lung Cancer clinical trials directory page